JP2008515994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515994A5 JP2008515994A5 JP2007536899A JP2007536899A JP2008515994A5 JP 2008515994 A5 JP2008515994 A5 JP 2008515994A5 JP 2007536899 A JP2007536899 A JP 2007536899A JP 2007536899 A JP2007536899 A JP 2007536899A JP 2008515994 A5 JP2008515994 A5 JP 2008515994A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- group
- alkenyl
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 46
- 125000003342 alkenyl group Chemical group 0.000 claims 27
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 108020002202 Adenosylhomocysteinase Proteins 0.000 claims 16
- 102000005234 Adenosylhomocysteinase Human genes 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 13
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 8
- 229920002554 vinyl polymer Polymers 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 239000013037 reversible inhibitor Substances 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- -1 —NH 2 Substances 0.000 claims 5
- 102000004157 Hydrolases Human genes 0.000 claims 4
- 108090000604 Hydrolases Proteins 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 206010029240 Neuritis Diseases 0.000 claims 4
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000005951 type IV hypersensitivity Effects 0.000 claims 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 4
- 102100020925 Adenosylhomocysteinase Human genes 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- NWPWVFAEENVVJM-UHFFFAOYSA-N Deoxyeritadenine Chemical compound NC1=NC=NC2=C1N=CN2CCC(O)C(O)=O NWPWVFAEENVVJM-UHFFFAOYSA-N 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims 2
- 230000002364 anti-haemorrhagic effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 230000006965 reversible inhibition Effects 0.000 claims 2
- 238000005094 computer simulation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000031261 interleukin-10 production Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *c1nc2c(*)nc(*)cc2[n]1**=* Chemical compound *c1nc2c(*)nc(*)cc2[n]1**=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/964,236 US7517887B2 (en) | 2003-04-09 | 2004-10-13 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
| US10/964,236 | 2004-10-13 | ||
| PCT/US2005/036890 WO2006044573A2 (en) | 2004-10-13 | 2005-10-13 | Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012153898A Division JP2012197314A (ja) | 2004-10-13 | 2012-07-09 | Ｓ−アデノシル−ｌ−ホモシステイン加水分解酵素の可逆的阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515994A JP2008515994A (ja) | 2008-05-15 |
| JP2008515994A5 true JP2008515994A5 (enExample) | 2008-11-27 |
| JP5270163B2 JP5270163B2 (ja) | 2013-08-21 |
Family
ID=36203526
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536899A Expired - Fee Related JP5270163B2 (ja) | 2004-10-13 | 2005-10-13 | Ｓ−アデノシル−ｌ−ホモシステイン加水分解酵素の可逆的阻害剤およびその使用 |
| JP2012153898A Withdrawn JP2012197314A (ja) | 2004-10-13 | 2012-07-09 | Ｓ−アデノシル−ｌ−ホモシステイン加水分解酵素の可逆的阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012153898A Withdrawn JP2012197314A (ja) | 2004-10-13 | 2012-07-09 | Ｓ−アデノシル−ｌ−ホモシステイン加水分解酵素の可逆的阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7517887B2 (enExample) |
| EP (1) | EP1799682B1 (enExample) |
| JP (2) | JP5270163B2 (enExample) |
| AU (1) | AU2005295704A1 (enExample) |
| CA (1) | CA2584209A1 (enExample) |
| WO (1) | WO2006044573A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517887B2 (en) | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
| US7868011B2 (en) * | 2003-04-09 | 2011-01-11 | General Atomics | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus |
| US7196093B2 (en) * | 2003-04-09 | 2007-03-27 | General Atomics | Reversible inhibitors of SAH hydrolase and uses thereof |
| TW200523262A (en) * | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| BRPI0615250A2 (pt) * | 2005-09-02 | 2011-05-10 | Pfizer | 1h-imidazopiridinas substituÍdas por hidràxi, composiÇço farmacÊutica contendo as mesmas, bem como seus usos |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008145159A1 (de) * | 2007-05-30 | 2008-12-04 | Sarstedt Aktiengesellschaft & Co. | Eine blutentnahmevorrichtung umfassend komponenten zur stabilisierung des homocysteinspiegels und/oder zur hemmung der fortlaufenden bildung von homocystein in blutproben, serumproben oder blutplasmaproben |
| CN101456860B (zh) | 2007-12-10 | 2011-02-16 | 中国科学院上海药物研究所 | 4-[9-(6-氨基嘌呤基)]-2(s)-羟基丁酸甲酯的制备方法 |
| TWI386204B (zh) * | 2008-04-10 | 2013-02-21 | Mitsubishi Tanabe Pharma Corp | 高半胱胺酸合成酶抑制劑 |
| MY161598A (en) * | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| WO2011043480A1 (ja) * | 2009-10-09 | 2011-04-14 | 田辺三菱製薬株式会社 | ホモシステイン合成酵素阻害薬 |
| WO2011156889A1 (en) * | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| CN117045661B (zh) * | 2023-10-11 | 2024-01-30 | 广东医科大学附属医院 | Sahh可逆型抑制剂的应用、药物组合物及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756914A (fr) * | 1969-10-25 | 1971-03-30 | Fujisawa Pharmaceutical Co | Nouveaux derives de l'adenine et leurs sels |
| SE8404768L (sv) * | 1983-09-27 | 1985-03-28 | Ceskoslovenska Akademie Ved | 9-(aminoalkyl)-8-hydroxiadeniner och sett for deras framstellning |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| JPH0374330A (ja) * | 1989-08-11 | 1991-03-28 | Snow Brand Milk Prod Co Ltd | 脱髄疾患治療剤 |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5641783A (en) * | 1993-11-12 | 1997-06-24 | Cell Therapeutics, Inc. | Substituted amino alcohol compounds |
| US6020337A (en) * | 1993-04-05 | 2000-02-01 | Cell Therapeutics, Inc. | Electronegative-substituted long chain xanthine compounds |
| DE69402548T2 (de) | 1993-06-21 | 1997-07-17 | Merrell Pharma Inc | Carbocyclische nucleoside mittel nützlich als selektive inhibitoren von proinflammatorischen cytokinen |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| US5941868A (en) | 1995-12-22 | 1999-08-24 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US5668173A (en) | 1996-02-23 | 1997-09-16 | The Board Of Trustees Of The University Of Illinois Corp. | Method of increasing the conversion of homocysteine to methionine and uses thereof |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| US6429212B1 (en) * | 1996-08-16 | 2002-08-06 | Ishihara Sangyo Kaisha Ltd. | Medicinal composition |
| EP1019501A1 (en) * | 1997-03-14 | 2000-07-19 | Otsuka Pharmaceutical Co., Ltd. | Novel pyrimidine derivative |
| EP0969743B1 (en) | 1997-03-20 | 2004-09-15 | Coventry Group, Ltd. | Nutritional supplement for cardiovascular health |
| US5854023A (en) | 1997-07-17 | 1998-12-29 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding human S-adenosyl-5-homocysteine hydrolase derived from bladder |
| US6066467A (en) | 1997-07-24 | 2000-05-23 | Anticancer, Inc. | High specificity homocysteine assays for biological samples |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| EP1029851B1 (en) * | 1997-10-14 | 2005-04-20 | Mitsubishi Pharma Corporation | Piperazine compounds and medicinal use thereof |
| GB9724838D0 (en) * | 1997-11-26 | 1998-01-21 | Franks Christopher R | Compositions |
| US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| US5962274A (en) | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
| WO1999050238A1 (en) * | 1998-03-26 | 1999-10-07 | Santen Pharmaceutical Co., Ltd. | Novel urea derivatives |
| EP1076649A4 (en) * | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| US6353003B1 (en) | 1998-06-17 | 2002-03-05 | Eli Lilly And Company | Method for reducing levels of homocysteine and C-reactive protein |
| US6323188B1 (en) | 1998-07-01 | 2001-11-27 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins |
| US6210686B1 (en) | 1998-12-18 | 2001-04-03 | Beth Israel Deaconess Medical Center | Dietary supplement and method for lowering risk of heart disease |
| US6274170B1 (en) | 1999-02-18 | 2001-08-14 | Richard Heibel | Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same |
| WO2000064479A1 (en) | 1999-04-27 | 2000-11-02 | Antibody Systems, Inc. | Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US6361800B1 (en) | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
| US6337317B1 (en) * | 2000-06-27 | 2002-01-08 | The University Of British Columbia | Antimicrobial peptides and methods of use thereof |
| CA2488801A1 (en) * | 2002-06-07 | 2003-12-18 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
| US7517887B2 (en) | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
| US7868011B2 (en) | 2003-04-09 | 2011-01-11 | General Atomics | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus |
| US7196093B2 (en) * | 2003-04-09 | 2007-03-27 | General Atomics | Reversible inhibitors of SAH hydrolase and uses thereof |
-
2004
- 2004-10-13 US US10/964,236 patent/US7517887B2/en not_active Expired - Lifetime
-
2005
- 2005-10-13 EP EP05814804A patent/EP1799682B1/en not_active Expired - Lifetime
- 2005-10-13 CA CA002584209A patent/CA2584209A1/en not_active Abandoned
- 2005-10-13 WO PCT/US2005/036890 patent/WO2006044573A2/en not_active Ceased
- 2005-10-13 AU AU2005295704A patent/AU2005295704A1/en not_active Abandoned
- 2005-10-13 JP JP2007536899A patent/JP5270163B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-09 JP JP2012153898A patent/JP2012197314A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515994A5 (enExample) | ||
| JP2007534636A5 (enExample) | ||
| JP2007515405A5 (enExample) | ||
| JP2007535491A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2013523765A5 (enExample) | ||
| CA2545427A1 (en) | Selective kinase inhibitors | |
| JP2013521279A5 (enExample) | ||
| JP2015520767A5 (enExample) | ||
| JP2005053931A5 (enExample) | ||
| JP2008504265A5 (enExample) | ||
| JP2008505157A5 (enExample) | ||
| JP2005533028A5 (enExample) | ||
| CA2669481A1 (en) | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels | |
| JP2002519355A5 (enExample) | ||
| JP2010510171A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| US20160271162A1 (en) | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv | |
| JP2004131511A5 (enExample) | ||
| JP5744003B2 (ja) | 抗ウイルス化合物を調製する方法 | |
| JP2004529172A5 (enExample) | ||
| JP2013503881A5 (enExample) | ||
| CN101443332B (zh) | 抗病毒嘧啶核苷衍生物 | |
| JP2007519654A5 (enExample) | ||
| JP2006517932A5 (enExample) |